Citation: An Lu, Yuhao Guo, Yi Yan, Lin Zhai, Xiangyu Wang, Weiran Cao, Zijie Li, Zhixia Zhao, Yujie Shi, Yuanjun Zhu, Xiaoyan Liu, Huining He, Zhiyu Wang, Jian-Cheng Wang. Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy[J]. Chinese Chemical Letters, ;2024, 35(6): 108928. doi: 10.1016/j.cclet.2023.108928 shu

Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy

An Lu ^{a, 1} ,
Yuhao Guo ^{a, 1} ,
Yi Yan ^{a, 1} ,
Lin Zhai ^a ,
Xiangyu Wang ^a ,
Weiran Cao ^b ,
Zijie Li ^c ,
Zhixia Zhao ^d ,
Yujie Shi ^a ,
Yuanjun Zhu ^a ,
Xiaoyan Liu ^a ,
Huining He ^b ,
Zhiyu Wang ^c ,
Jian-Cheng Wang ^{a, e, *,}

a.
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
b.
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China
c.
Department of Immuno-oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
d.
Department of Pharmacy, Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing 100029, China
e.
Laboratory of innovative formulations and pharmaceutical excipients, Ningbo Institute of Marine Medicine, Peking University, Ningbo 315832, China

wang-jc@bjmu.edu.cn

Received Date: 8 May 2023
Revised Date: 2 August 2023
Accepted Date: 9 August 2023
Available Online: 12 August 2023

Figures(5)

Immunosuppressive microenvironments present critical problems in clinical chemotherapy. To regulate the tumor immune microenvironment for enhancing antitumor effect, a combination of immune checkpoint inhibitors (ICIs) with chemotherapeutics has been applied clinically. In this study, miriplatin (MiPt), the lipidic derivative of 5-fluorouracil (Fu-OA), as well as the programmed death ligand 1 (PD-L1) target siRNA (siPD-L1) were integrated into Lip-Pt/Fu@siPD-L1 nanoparticles (NPs) for chemo-immunotherapy. In vitro results showed that Lip-Pt/Fu@siPD-L1 NPs could exhibit effective siRNA gene silencing and promote the phagocytosis of tumor cells by macrophages. Furthermore, in vivo results revealed that Lip-Pt/Fu@siPD-L1 NPs showed significantly higher anti-tumor efficiency than that of the physical mixing of MiPt, 5-fluorouracil, and Lip@siPD-L1 NPs (delivery of siPD-L1 by liposomes). The best anti-tumor efficiency of Lip-Pt/Fu@siPD-L1 NPs resulted from the synergistic immunotherapeutic effects of MiPt and siPD-L1 based on the inhibition of CD47 expression and the downregulation of PD-L1 in tumor cells, which elicited a robust anti-tumor immune response through the activation of macrophage phagocytosis and immune checkpoint inhibition. The Lip-Pt/Fu@siPD-L1 NPs provide a potential strategy for tumor chemo-immunotherapy.
- Chemo-immunotherapy,
- Immune checkpoint inhibition,
- Gene silencing,
- Miriplatin,
- Macrophage phagocytosis,
- Nanotechnology
1. [1]
  R. Zhang, X.Q. Song, R.P. Liu, Z.Y. Ma, J.Y. Xu, J. Med. Chem. 62 (2019) 4543–4554. doi: 10.1021/acs.jmedchem.9b00128
2. [2]
  T.A. Seidu, P.T. Kutoka, D.O. Asante, et al., Pharmaceutics 14 (2022) 1113. doi: 10.3390/pharmaceutics14051113
3. [3]
  R.G. Kenny, C.J. Marmion, Chem. Rev. 119 (2019) 1058–1137. doi: 10.1021/acs.chemrev.8b00271
4. [4]
  Y. Shi, Z. Zhao, K. Peng, et al., Adv. Healthc. Mater. 10 (2021) e2001455. doi: 10.1002/adhm.202001455
5. [5]
  Y. Tian, Q. Zhao, Y. Li, et al., Gastroenterol. Res. Pract. 2021 (2021) 5590626. doi: 10.1155/2021/5590626
6. [6]
  X. Sun, Y. Wang, T. Du, et al., Chin. Chem. Lett. 34 (2023) 108201. doi: 10.1016/j.cclet.2023.108201
7. [7]
  H. Nasrolahi, S. Mirzaei, M. Mohammadianpanah, et al., Ann. Coloproctol. 35 (2019) 242–248. doi: 10.3393/ac.2018.09.06
8. [8]
  L. Fournel, Z. Wu, N. Stadler, et al., Cancer Lett. 464 (2019) 5–14. doi: 10.1016/j.canlet.2019.08.005
9. [9]
  E. Bockamp, S. Rosigkeit, D. Siegl, D. Schuppan, Cells 9 (2020) 2102. doi: 10.3390/cells9092102
10. [10]
  L. Zhou, M. Zou, Y. Xu, et al., Front. Oncol. 12 (2022) 864301. doi: 10.3389/fonc.2022.864301
11. [11]
  L. Zhai, Y. Shi, Y. Yan, et al., Chin. Chem. Lett. 34 (2023) 108104. doi: 10.1016/j.cclet.2022.108104
12. [12]
  Y.S. Harada K. Kato K, Future Oncol. 18 (2022) 2311–2319. doi: 10.2217/fon-2022-0108
13. [13]
  A. Abed, M. Derakhshan, M. Karimi, et al., Front. Pharmacol. 13 (2022) 797804. doi: 10.3389/fphar.2022.797804
14. [14]
  Y. Xue, S. Gao, J. Gou, et al., Expert Opin. Drug Deliv. 18 (2021) 187–203. doi: 10.1080/17425247.2021.1825376
15. [15]
  V. Novohradsky, J. Pracharova, J. Kasparkova, et al., Inorg. Chem. Front. 7 (2020) 4150–4159. doi: 10.1039/d0qi00991a
16. [16]
  X. Huang, L. Han, R. Wang, et al., Drug Deliv. 29 (2022) 1358–1369. doi: 10.1080/10717544.2022.2069877
17. [17]
  J. Guo, Z. Yu, M. Das, L. Huang, ACS Nano 14 (2020) 5075–5089. doi: 10.1021/acsnano.0c01676
18. [18]
  J. Guo, Z. Yu, D. Sun, et al., Mol. Cancer 20 (2021) 10. doi: 10.1186/s12943-020-01297-0
19. [19]
  Y. Zhang, D. Hu, S. Han, et al., Exp. Biol. Med. 241 (2016) 1169–76. doi: 10.1177/1535370215625473
20. [20]
  S. Liu, Y. Li, X. Wang, et al., J. Pharm. Sci. 105 (2016) 78–87. doi: 10.1016/j.xphs.2015.10.026
21. [21]
  X. Kang, H.H. Xiao, H.Q. Song, et al., Cancer Biol. Med. 12 (2015) 362–374.
22. [22]
  A.G. Niculescu, A.M. Grumezescu, Int. J. Mol. Sci. 23 (2022) 5253. doi: 10.3390/ijms23095253
23. [23]
  Y. Shi, A. Lu, X. Wang, et al., Acta Pharm. Sin. B 11 (2021) 2396–2415. doi: 10.1016/j.apsb.2021.05.002
24. [24]
  X. Ling, W. Han, X. Jiang, et al., Biomaterials 270 (2021) 120690. doi: 10.1016/j.biomaterials.2021.120690
25. [25]
  J. Zuo, X. Gao, J. Xiao, Y. Cheng, Chin. Chem. Lett. 34 (2023) 107827. doi: 10.1016/j.cclet.2022.107827
26. [26]
  R. Zhang, G. Cheng, S. Liu, H. Lv, J. Li, J. Mater. Chem. B 9 (2021) 8809–8822. doi: 10.1039/d1tb01820e
27. [27]
  Y. Yan, A. Lu, Y. Dou, et al., Adv. Sci. 10 (2023) e2207490. doi: 10.1002/advs.202207490
1. [1]
  Ling Yang , Min Ren , Jie Wang , Liming He , Shanshan Wu , Shuai Yang , Wei Zhao , Hao Cheng , Xiaoming Zhou , Maling Gou . A non-viral gene therapy for melanoma by staphylococcal enterotoxin A. Chinese Chemical Letters, 2024, 35(5): 108822-. doi: 10.1016/j.cclet.2023.108822
2. [2]
  Feifei Wang , Hang Yao , Xinyue Wu , Yijian Tang , Yang Bai , Hui Chong , Huan Pang . Metal–organic framework and its composites modulate macrophage polarization in the treatment of inflammatory diseases. Chinese Chemical Letters, 2024, 35(5): 108821-. doi: 10.1016/j.cclet.2023.108821
3. [3]
  Yan Liu , Yang Wang , Jiayi Zhu , Xuxian Su , Xudong Lin , Liang Xu , Xiwen Xing . Employing pH-responsive RNA triplex to control CRISPR/Cas9-mediated gene manipulation in mammalian cells. Chinese Chemical Letters, 2024, 35(9): 109427-. doi: 10.1016/j.cclet.2023.109427
4. [4]
  Jie ZHANG , Xin LIU , Zhixin LI , Yuting PEI , Yuqi YANG , Huimin LI , Zhiqiang LIU . Assembling a luminescence silencing system based on post-synthetic modification strategy: A highly sensitive and selective turn-on metal-organic framework probe for ascorbic acid detection. Chinese Journal of Inorganic Chemistry, 2024, 40(4): 823-833. doi: 10.11862/CJIC.20230310
5. [5]
  Zhili Li , Qijun Wo , Dongdong Huang , Dezhong Zhou , Lei Guo , Yeqing Mao . Improving gene transfection efficiency of highly branched poly(β-amino ester)s through the in-situ conversion of inactive terminal groups. Chinese Chemical Letters, 2024, 35(8): 109737-. doi: 10.1016/j.cclet.2024.109737
6. [6]
  Yuxin Tian , Mengjun Li , Yang Yang , Chunhui Li , Yun Peng , Haiyin Yang , Mengyuan Zhao , Pengfei Wu , Shaobo Ruan , Yuanyu Huang , Chenguang Shen , Minghui Yang . An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus. Chinese Chemical Letters, 2024, 35(8): 109270-. doi: 10.1016/j.cclet.2023.109270
7. [7]
  Fanxin Kong , Hongzhi Wang , Huimei Duan . Inhibition effect of sulfation on Pt/TiO2 catalysts in methane combustion. Chinese Journal of Structural Chemistry, 2024, 43(5): 100287-100287. doi: 10.1016/j.cjsc.2024.100287
8. [8]
  Zhaomin Tang , Qian He , Jianren Zhou , Shuang Yan , Li Jiang , Yudong Wang , Chenxing Yao , Huangzhao Wei , Keda Yang , Jiajia Wang . Active-transporting of charge-reversal Cu(Ⅱ)-doped mesoporous silica nanoagents for antitumor chemo/chemodynamic therapy. Chinese Chemical Letters, 2024, 35(7): 109742-. doi: 10.1016/j.cclet.2024.109742
9. [9]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
10. [10]
  Yuanyi Zhou , Ke Ma , Jinfeng Liu , Zirun Zheng , Bo Hu , Yu Meng , Zhizhong Li , Mingshan Zhu . Is reactive oxygen species the only way for cancer inhibition over single atom nanomedicine? Autophagy regulation also works. Chinese Chemical Letters, 2024, 35(6): 109056-. doi: 10.1016/j.cclet.2023.109056
11. [11]
  Xinpin Pan , Yongjian Cui , Zhe Wang , Bowen Li , Hailong Wang , Jian Hao , Feng Li , Jing Li . Robust chemo-mechanical stability of additives-free SiO₂ anode realized by honeycomb nanolattice for high performance Li-ion batteries. Chinese Chemical Letters, 2024, 35(10): 109567-. doi: 10.1016/j.cclet.2024.109567
12. [12]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672

Get Citation

PDF

XML

Metrics

PDF Downloads(1)
Abstract views(133)
HTML views(5)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142